XML 42 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Agreements (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
1 Months Ended 6 Months Ended 137 Months Ended 6 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 0 Months Ended 0 Months Ended
Mar. 31, 2012
Mar. 31, 2010
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2013
GSK
item
Oct. 28, 2010
GSK
Original Collaboration Agreement
Oct. 31, 2010
GSK
Original Collaboration Agreement
Jul. 17, 2012
GSK
Expanded Collaboration Agreement
item
Jul. 31, 2012
GSK
Expanded Collaboration Agreement
Jun. 30, 2013
GSK
Expanded Collaboration Agreement
Jul. 26, 2012
GSK
SPA
Jul. 17, 2012
GSK
SPA
Jul. 31, 2012
GSK
SPA
Jun. 30, 2013
GSK
SPA
Jun. 30, 2012
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
Sep. 30, 2012
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
Original Collaboration Agreement
Oct. 28, 2010
GSK
Clinical development objectives and the acceptance of regulatory filings milestone
Original Collaboration Agreement
Oct. 28, 2010
GSK
Market approvals for migalastat HCl milestone
Original Collaboration Agreement
Oct. 28, 2010
GSK
Achievement of certain sales thresholds milestone
Original Collaboration Agreement
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
Expanded Collaboration Agreement
Jul. 17, 2012
GSK
U.S. regulatory approval milestones for migalastat HCl monotherapy and migalastat HCl-ERT co-administration
Expanded Collaboration Agreement
Maximum
Collaborative Agreements                                            
Upfront payment received           $ 30,000,000                                
Potential milestone payments receivable           173,500,000                     13,500,000 80,000,000 80,000,000   20,000,000  
Percentage of development costs funded by the entity               40.00%                            
Stock issued from collaboration agreement (in shares)   4.90       6.90 6.87         2.90 2.90                  
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) $ 5.70 $ 3.74       $ 4.56 $ 4.56         $ 6.30 $ 6.30                  
Percentage of premium on average price per share of common stock issued as part of the license and collaboration agreement           30.00%                                
Period preceding the closing date of the transaction over which average price per share of the company's stock is used           60 days                                
Total value of the equity investment to the company 62,000,000   62,057,000 193,441,000   31,000,000 31,000,000   18,600,000                          
Ownership position in the company (as a percent)                   19.80%       19.80%                
Number of accounting units         1                                  
Milestone revenue recognized                             3,500,000              
Number of exclusive licenses               2                            
Additional potential milestone payments receivable                                           35,000,000
Potential milestone payments received                               3,500,000            
Period of additional potential milestone payments receivable                                           7 years
Percentage of development costs funded by the entity in 2012                                       25.00%    
Percentage of development costs funded by the counterparty in 2012                                       75.00%    
Percentage of development costs funded by the entity, thereafter                                       40.00%    
Percentage of development costs funded by the counterparty, thereafter                                       60.00%    
Percentage of development costs funded by the counterparty               60.00%                            
Total purchase price (in dollars)                     $ 18,600,000 $ 18,600,000                    
Lock-up period for common stock issued as a part of SPA                     6 months